Strong Anti‐tumor Effect of Monosialoganglioside Specific Monoclonal Antibody 202: A Clinical Trial in a Cancer Patient with Melanoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1346-8138|16|6|480-486

ISSN： 0385-2407

Source： THE JOURNAL OF DERMATOLOGY, Vol.16, Iss.6, 1989-12, pp. : 480-486

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Polysialogangliosides Expressed by Amelanotic Melanoma: A Possible Explanation for the Poor Response to Anti‐monosialoganglioside Antibody 202 in a Patient with Melanoma

By  

THE JOURNAL OF DERMATOLOGY, Vol. 22, Iss. 2, 1995-02 ,pp. : 81-87

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Application of Anti-CCR4 Monoclonal Antibody

By  

Oncology, Vol. 89, Iss. 1, 2015-0 ,pp. : 16-21

Karger

Access to resources Recommend Favorite

Active Specific Immunotherapy of Malignant Melanoma with Anti‐idiotypic Monoclonal Antibodies

By  

THE JOURNAL OF DERMATOLOGY, Vol. 20, Iss. 9, 1993-09 ,pp. : 533-539

John Wiley & Sons Inc

Access to resources Recommend Favorite

Current Status of Pharmacogenomics Testing for Anti-Tumor Drug Therapies: Approaches to Non-Melanoma Skin Cancer

By Grealy Rebecca   Griffiths Lyn R.  

Molecular Diagnosis & Therapy, Vol. 13, Iss. 2, 2009-04 ,pp. : 65-72

Adis International

Access to resources Recommend Favorite

New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment

By  

Oncology Research and Treatment, Vol. 37, Iss. 6, 2014-05 ,pp. : 351-353

Karger

Access to resources Recommend Favorite